Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “HER2 Positive Early or Locally Advanced Breast Cancer”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Testing effectiveness (Phase 2)Study completedNCT04836520
What this trial is testing

SHR6390 Combined With Anastrozole for Preoperative Treatment of Breast Cancer.

Who this might be right for
Breast Cancer
Tianjin Medical University Cancer Institute and Hospital 20
Testing effectiveness (Phase 2)Study completedNCT00943670
What this trial is testing

Corrected QT Interval Effects of Trastuzumab Emtansine (T-DM1) in Patients With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Locally Advanced or Metastatic Breast Cancer and the Safety and Tolerability of Combined T-DM1 and Pertuzumab in Patients With Early Disease Progression

Who this might be right for
Metastatic Breast Cancer
Genentech, Inc. 51
Testing effectiveness (Phase 2)Looking for participantsNCT05834764
What this trial is testing

Pyrotinib in Women With High-risk in Early Stage Breast Cancer

Who this might be right for
HER2-positive Breast Cancer
The First Affiliated Hospital with Nanjing Medical University 188
Not applicableEnded earlyNCT06126003
What this trial is testing

Gut and Tumor Microbiome in Patients With Early Stage (II-III), Locally Advanced or Advanced ER-positive and HER2-negative Breast Cancer.

Who this might be right for
Breast Cancer
BioCorteX Inc 2
Testing effectiveness (Phase 2)Looking for participantsNCT06927180
What this trial is testing

SHR-A1811 Plus Pertuzumab in the Neoadjuvant Treatment of HER2 Positive BC

Who this might be right for
Breast Cancer Early Stage Breast Cancer (Stage 1-3)
Henan Cancer Hospital 180
Not applicableUnknownNCT03947242
What this trial is testing

Neoadjuvant Study of Pyrotinib and Trastuzumab Plus Vinorelbine in Trastuzumab-refractory HER2-Positive Breast Cancer.

Who this might be right for
HER2 Positive Breast Cancer
Henan Cancer Hospital 48
Large-scale testing (Phase 3)Not Yet RecruitingNCT07294534
What this trial is testing

A Phase II/III Clinical Study to Evaluate the Efficacy and Safety of HLX87in Combination With HLX22 or Pertuzumab in the Neoadjuvant Therapy of HER2-Positive Bresat Cancer

Who this might be right for
HER2 + Breast Cancer
Shanghai Henlius Biotech 817
Large-scale testing (Phase 3)Active Not RecruitingNCT06747338
What this trial is testing

A Phase III Study of KN026 in Combination With HB1801 ± Carboplatin as Neoadjuvant Treatment for Early or Locally Advanced HER2-Positive Breast Cancer

Who this might be right for
Early or Locally Advanced HER2-positive Breast Cancer
Shanghai JMT-Bio Inc. 520
Early research (Phase 1)Study completedNCT02605915
What this trial is testing

Safety and Pharmacokinetics of Atezolizumab Combination Treatments in Participants With HER2-Positive and HER2-Negative Breast Cancer

Who this might be right for
HER2-Positive Metastatic Breast CancerHER2-Negative Metastatic Breast CancerLocally Advanced or Early Breast Cancer
Hoffmann-La Roche 98
Testing effectiveness (Phase 2)Study completedNCT02132949
What this trial is testing

A Study Evaluating Pertuzumab (Perjeta) Combined With Trastuzumab (Herceptin) and Standard Anthracycline-based Chemotherapy in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Locally Advanced, Inflammatory, or Early-stage Breast Cancer

Who this might be right for
Breast Cancer
Hoffmann-La Roche 401
Testing effectiveness (Phase 2)UnknownNCT04881929
What this trial is testing

Study of KN026 in Combination With Docetaxel as Neoadjuvant Therapy in HER2-positive Breast Cancer

Who this might be right for
Breast Cancer
Jiangsu Alphamab Biopharmaceuticals Co., Ltd 30
Post-approval studies (Phase 4)Not Yet RecruitingNCT07589699
What this trial is testing

Trastuzumab Rezetecan (T-DXh) in HER2+ Breast Cancer With Non-pCR After TCbHP

Who this might be right for
Breast CancerHER2-positive Breast CancerEarly-stage Breast Cancer+1 more
The First Affiliated Hospital with Nanjing Medical University 59
Large-scale testing (Phase 3)Study completedNCT03989037
What this trial is testing

SIBP-01 Or CN-Trastuzumab Plus Docetaxel And Carboplatin In HER2 Positive Breast Cancer

Who this might be right for
HER2-positive Early Breast Cancer
Shanghai Institute Of Biological Products 580
Large-scale testing (Phase 3)Ended earlyNCT06038539
What this trial is testing

Efficacy and Safety of the Proposed Biosimilar Pertuzumab (PERT-IJS) Versus EU-Perjeta® Along With Trastuzumab and Chemotherapy (Carboplatin and Docetaxel) as Neoadjuvant Treatment in Chemotherapy naïve Patients With Early Stage or Locally Advanced HR Negative and HER2 Positive Breast Cancer

Who this might be right for
HR Negative HER2 Positive Early Breast Cancer or Locally Advanced Breast Cancer Patients
Biocon Biologics UK Ltd 55
Testing effectiveness (Phase 2)Study completedNCT00545688
What this trial is testing

Pertuzumab in Combination With Herceptin in Patients With HER2 Positive Breast Cancer.

Who this might be right for
Breast Cancer
Hoffmann-La Roche 417
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07307287
What this trial is testing

SHR-A1811 Plus Pertuzumab as Neoadjuvant Therapy for Early or Locally Advanced HR-Positive HER2-Positive Breast Cancer: A Prospective, Open-Label, Phase II Study

Who this might be right for
SHR-A1811HER2-Postive Breast CancerHR+ Breast Cancer+2 more
Tianjin Medical University Cancer Institute and Hospital 30
Not applicableStudy completedNCT03025711
What this trial is testing

Outcomes Of The Spanish Cohort Of Early Access To Pertuzumab And Trastuzumab Emtansine

Who this might be right for
Breast Neoplasms
BELEN RUIZ-ANTORAN 220
Not applicableEnded earlyNCT02771795
What this trial is testing

A Long-term Follow-up Study for Cardiac Safety in the Patients With HER2 (+) Breast Cancer Who Have Completed the SB3-G31-BC

Who this might be right for
Breast Neoplasms
Samsung Bioepis Co., Ltd. 538
Testing effectiveness (Phase 2)Active Not RecruitingNCT04398914
What this trial is testing

Pyrotinib, Trastuzumab, Pertuzumab and Nab-paclitaxel as Neoadjuvant Therapy in HER2-positive Breast Cancer

Who this might be right for
Breast Cancer Invasive
Shanghai Jiao Tong University School of Medicine 216
Large-scale testing (Phase 3)Active Not RecruitingNCT07196774
What this trial is testing

A Trial of SHR-A1811 Compared to Other Antitumor Therapies as Neoadjuvant Treatments in Early-stage or Locally Advanced HER2-positive Breast Cancer

Who this might be right for
Early-stage or Locally Advanced HER2-positive Breast Cancer
Jiangsu HengRui Medicine Co., Ltd. 740
Next Page